| Title | Intervention |
NCT ID |
Sponsor | Status |
|---|---|---|---|---|
| Reproductive Health Program in Patients With Cancer | educational intervention, quality-of-life assessment, questionnaire administration | NCT01806129 | Eastern Cooperative Oncology Group | Active, not recruiting |
| A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) | anastrozole, questionnaire administration, laboratory biomarker analysis, pharmacogenomic studies | NCT01824836 | Eastern Cooperative Oncology Group | Active, not recruiting |
| Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In... | metformin hydrochloride, placebo | NCT01905046 | Alliance for Clinical Trials in Oncology | Recruiting |
| Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk | Metformin, Placebo | NCT02028221 | University of Arizona | Active, not recruiting |
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation | Pamidronate, Calcium and vitamin D | NCT02074631 | Masonic Cancer Center, University of Minnesota | Recruiting |
| Meaning-Centered Counseling for Chinese Patients Who Are Being Treated for Advanced Cancer | Adaptation of IMCP for Chinese Immigrant Cancer Patients, In-depth Patient Interviews, Individual Meaning-Centered Psychotherapy for Chinese (IMCP-Ch) (For Phase 3) | NCT02112188 | Memorial Sloan Kettering Cancer Center | Recruiting |
| Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps | Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment, Saline | NCT02134925 | National Cancer Institute (NCI) | Active, not recruiting |
| Iloprost in Preventing Lung Cancer in Former Smokers | Iloprost, Quality-of-Life Assessment, Questionnaire Administration, Placebo Administration | NCT02237183 | National Cancer Institute (NCI) | Active, not recruiting |
| Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment | NCT02273362 | National Cancer Institute (NCI) | Active, not recruiting |
| Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast... | Endocrine therapy interruption | NCT02308085 | International Breast Cancer Study Group | Active, not recruiting |
Why I Joined a Clinical Trial
Hi, my name is Raffaellina and [am here] thanks to the European Institute of Oncology and to the research! I am 76 years old and I have been diagnosed [with] breast cancer. I have chosen to participate into a clinical trial because of the clear and accurate explanation of my options and future perspectives and for the confidence in research transmitted by the Team I felt as aā human beingā and not as a ānumberā, and this feeling has not changed afterwards. I was so scared about my future, but when the team proposed me to participate in the study, I have accepted it with enthusiasm. No adverse event occurred, and moreover, I have experienced benefit that impacted the definitive surgery. We need to trust and support clinical research!